{"id":"NCT00258908","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan","officialTitle":"Immunogenicity and Safety of ADACEL™ (TdcP Vaccine) as Fifth Dose in Children 6-8 Years of Age.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11","primaryCompletion":"2006-08","completion":"2006-08","firstPosted":"2005-11-28","resultsPosted":"2009-06-08","lastUpdate":"2016-04-14"},"enrollment":115,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis"],"interventions":[{"type":"BIOLOGICAL","name":"Diphteria, tetanus, and Acellular Pertussis vaccine","otherNames":["ADACEL™"]}],"arms":[],"summary":"To assess the immunogenicity profile of ADACEL™, Tetanus and Diphtheria Toxoids Adsorbed combined with Component Pertussis Vaccine (TdcP Vaccine) one month after administration.\n\nTo describe the safety profile of ADACEL™ (TdcP Vaccine) when given as a fifth dose.","primaryOutcome":{"measure":"Percentage of Participants With Antibody (Anti-diphtheria, Anti-tetanus, and Anti-pertussis Toxoids) Responses Pre- and Post-vaccination","timeFrame":"Day 0 and Day 28 Post-vaccination","effectByArm":[{"arm":"ADACEL™ Group","deltaMin":95,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":1,"countries":["Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":112},"commonTop":["Nasopharyngitis"]}}